ltimos avances en hepatología.
Bartolomé J, Quiroga JA,Carreño V.Hepatol Clin 1996; 4: 215-240.
Recombinant human granulocyte colony-stimulating factor reduces hepatitis C virus replication in mononuclear cells from chronic hepatitis C patients.
Martín J, Navas S, Quiroga JA,Carreño V. Cytokine 1996; 8: 313-317
Patterns of immune responses to the host-encoded GOR and hepatitis C virus core-derived epitopes with relation to hepatitis C viremia, genotypes and liver disease severity
Quiroga JA, Pardo M, Navas S, Martín J,Carreño V. J Infect Dis 1996; 173: 300-305.
Risk and benefits of interferon-alpha in the treatment of hepatitis
Pardo M, Marriott E, Moliner MC, Quiroga JA,Carreño V. Drug Safety 1995; 13: 304-316.
Hepatitis C virus genotypes in serum and liver of children with chronic hepatitis C.
Castillo I, Bartolomé J, Ruiz-Moreno M, Sánchez V, Navas S,Carreño V. Pediatric Res 1995; 38: 618-620.
ltimos avances en hepatología.
Carreño V. Castillo I.Hepatol Clin 1995; 3: 91-118.
Factors predictive of response to interferon therapy in children with chronic hepatitis B.
Ruíz-Moreno M, Camps T, Jiménez J, López R, Castillo I, Bartolomé J,Carreño V. J Hepatol 1995; 22: 540-544.
Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon alpha
Pardo M, Castillo I, Navas S,Carreño V. J Med Virol 1995; 45: 439-444.
ltimos avances en hepatología.
Carreño V, Quiroga JA, Castillo I.Hepatol Clin1995; 3: 39-66.
Biologic response modifiers in chronic hepatitis C
Carreño V, Quiroga JA. J Hepatol 1995; 22: s122-s126.
Semiquantification by Amplicor TM assay of hepatitis C virus genome during therapy
Navas S,Carreño V. J Hepatol 1995; 22: s115-s117.
Ribozymes: structure, characteristics and use as potential antiviral agents
Bartolomé J, Madejón A,Carreño V. J Hepatol 1995; 22: s57-s64.
